InsiderSignalSign in

← Insider buys

APGE

Apogee Therapeutics, Inc. · Healthcare

Insiders sold $171.4M of Apogee Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$171.4MSold, 12 mo

$10.2BMarket cap

APGE over the last year

No insider buys filed in this year

APGE after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Every filing

43 insider filings since 2023, newest first

Carl Dambkowski · Chief Medical Officer

$738K−3.2%Aug 8

Michael Thomas Henderson · Chief Executive Officer

$2.7M−2.0%Jul 11

Carl Dambkowski · Chief Medical Officer

$730K−3.0%Jul 3

Carl Dambkowski · Chief Medical Officer

$3.5M−12.8%Jun 25

Michael Thomas Henderson · Chief Executive Officer

$10.6M−7.3%Jun 25

Michael Thomas Henderson · Chief Executive Officer

$1.7M−1.8%Jun 12

Carl Dambkowski · Chief Medical Officer

$433K−2.6%Jun 6

Michael Thomas Henderson · CEO

$1.6M−2.0%May 15

Carl Dambkowski · Chief Medical Officer

$463K−3.0%May 8

Jane Henderson · CFO

$164K−1.0%May 4

Jane Henderson · CFO

$180K−1.0%Apr 17

Michael Thomas Henderson · CEO

$1.7M−2.0%Apr 10

Carl Dambkowski · Chief Medical Officer

$467K−3.0%Apr 3

Jane Henderson · CFO

$170K−1.0%Apr 3

Jane Henderson · CFO

$170K−1.0%Mar 27

Michael Thomas Henderson · CEO

$1.5M−2.0%Mar 13

Carl Dambkowski · Chief Medical Officer

$391K−3.0%Mar 6

Jane Henderson · CFO

$140K−1.0%Mar 4

Michael Thomas Henderson · CEO

$1.3M−2.0%Feb 13

Fairmount Funds Management LLC · Director

$133.5M−81.0%Jan 22

Michael Thomas Henderson · CEO

$1.6M−2.0%Jan 16

Carl Dambkowski · Chief Medical Officer

$1.5M−8.0%Jan 9

Jane Henderson · CFO

$609K−4.0%Jan 6

Jane Henderson · CFO

$120K−1.0%Dec 23

Michael Thomas Henderson · CEO

$1.5M−2.0%Dec 12

Carl Dambkowski · Chief Medical Officer

$818K−4.0%Dec 5

Jane Henderson · CFO

$113K−1.0%Dec 5

Michael Thomas Henderson · CEO

$3.0M−3.0%Dec 5

Jane Henderson · CFO

$105K−1.0%Nov 28

Mark C. Mckenna · Director

Carl Dambkowski · Chief Medical Officer

$394K−2.0%Nov 8

Michael Thomas Henderson · CEO

$888K−1.0%Nov 8

Carl Dambkowski · Chief Medical Officer

$375K−2.0%Oct 4

Michael Thomas Henderson · CEO

$2.2M−3.0%Oct 4

Carl Dambkowski · Chief Medical Officer

$317K−2.0%Sep 6

Michael Thomas Henderson · CEO

$1.9M−3.0%Sep 6

Jane Henderson · CFO

$290K−3.0%Aug 23

Carl Dambkowski · Chief Medical Officer

$298K−2.0%Aug 9

Michael Thomas Henderson · CEO

$1.6M−3.0%Aug 9

Michael Thomas Henderson · CEO

$559K−1.0%Jul 5

Carl Dambkowski · Chief Medical Officer

$225K−2.0%Jul 5

Nimish P Shah · Director

Fairmount Funds Management LLC · Director

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.